Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2000 Sierra Point Parkway, Suite 501 BRISBANE CA 94080-1930 |
Tel: | N/A |
Website: | https://dayonebio.com |
IR: | See website |
Key People | ||
Garry A. Nicholson Chairman of the Board | Jeremy Bender President, Chief Executive Officer, Director | Samuel Blackman Co-Founder, Head of Research and Development |
Charles N. York Chief Financial Officer, Chief Operating Officer, Secretary | Lauren Merendino Chief Commercial Officer | Raphael F. Rousseau Chief Medical Officer |
Business Overview |
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company's lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company's pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older. |
Financial Overview |
For the fiscal year ended 31 December 2023, Day One Biopharmaceuticals Inc revenues was not reported. Net loss increased 33% to $188.9M. Higher net loss reflects Research and development increase of 51% to $116.1M (expense), General and administrative - Balancing increase of 19% to $50.6M (expense), Stock-based Compensation in SGA increase of 33% to $25M (expense). |
Employees: | 155 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $977.51M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$206.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$188.92M as of Dec 31, 2023 |
Free cash flow (TTM): | -$147.08M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 87,377,163 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |